Influence of temperature management at 33 °C versus normothermia on survival in patients with vasopressor support after out-of-hospital cardiac arrest: a post hoc analysis of the TTM-2 trial.
Cardiac arrest
Heart arrest
Hypothermia induced
Mortality
Shock
Sudden
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
31 07 2022
31 07 2022
Historique:
received:
21
03
2022
accepted:
25
07
2022
entrez:
31
7
2022
pubmed:
1
8
2022
medline:
3
8
2022
Statut:
epublish
Résumé
Targeted temperature management at 33 °C (TTM33) has been employed in effort to mitigate brain injury in unconscious survivors of out-of-hospital cardiac arrest (OHCA). Current guidelines recommend prevention of fever, not excluding TTM33. The main objective of this study was to investigate if TTM33 is associated with mortality in patients with vasopressor support on admission after OHCA. We performed a post hoc analysis of patients included in the TTM-2 trial, an international, multicenter trial, investigating outcomes in unconscious adult OHCA patients randomized to TTM33 versus normothermia. Patients were grouped according to level of circulatory support on admission: (1) no-vasopressor support, mean arterial blood pressure (MAP) ≥ 70 mmHg; (2) moderate-vasopressor support MAP < 70 mmHg or any dose of dopamine/dobutamine or noradrenaline/adrenaline dose ≤ 0.25 µg/kg/min; and (3) high-vasopressor support, noradrenaline/adrenaline dose > 0.25 µg/kg/min. Hazard ratios with TTM33 were calculated for all-cause 180-day mortality in these groups. The TTM-2 trial enrolled 1900 patients. Data on primary outcome were available for 1850 patients, with 662, 896, and 292 patients in the, no-, moderate-, or high-vasopressor support groups, respectively. Hazard ratio for 180-day mortality was 1.04 [98.3% CI 0.78-1.39] in the no-, 1.22 [98.3% CI 0.97-1.53] in the moderate-, and 0.97 [98.3% CI 0.68-1.38] in the high-vasopressor support groups with regard to TTM33. Results were consistent in an imputed, adjusted sensitivity analysis. In this exploratory analysis, temperature control at 33 °C after OHCA, compared to normothermia, was not associated with higher incidence of death in patients stratified according to vasopressor support on admission. Trial registration Clinical trials identifier NCT02908308 , registered September 20, 2016.
Sections du résumé
BACKGROUND
Targeted temperature management at 33 °C (TTM33) has been employed in effort to mitigate brain injury in unconscious survivors of out-of-hospital cardiac arrest (OHCA). Current guidelines recommend prevention of fever, not excluding TTM33. The main objective of this study was to investigate if TTM33 is associated with mortality in patients with vasopressor support on admission after OHCA.
METHODS
We performed a post hoc analysis of patients included in the TTM-2 trial, an international, multicenter trial, investigating outcomes in unconscious adult OHCA patients randomized to TTM33 versus normothermia. Patients were grouped according to level of circulatory support on admission: (1) no-vasopressor support, mean arterial blood pressure (MAP) ≥ 70 mmHg; (2) moderate-vasopressor support MAP < 70 mmHg or any dose of dopamine/dobutamine or noradrenaline/adrenaline dose ≤ 0.25 µg/kg/min; and (3) high-vasopressor support, noradrenaline/adrenaline dose > 0.25 µg/kg/min. Hazard ratios with TTM33 were calculated for all-cause 180-day mortality in these groups.
RESULTS
The TTM-2 trial enrolled 1900 patients. Data on primary outcome were available for 1850 patients, with 662, 896, and 292 patients in the, no-, moderate-, or high-vasopressor support groups, respectively. Hazard ratio for 180-day mortality was 1.04 [98.3% CI 0.78-1.39] in the no-, 1.22 [98.3% CI 0.97-1.53] in the moderate-, and 0.97 [98.3% CI 0.68-1.38] in the high-vasopressor support groups with regard to TTM33. Results were consistent in an imputed, adjusted sensitivity analysis.
CONCLUSIONS
In this exploratory analysis, temperature control at 33 °C after OHCA, compared to normothermia, was not associated with higher incidence of death in patients stratified according to vasopressor support on admission. Trial registration Clinical trials identifier NCT02908308 , registered September 20, 2016.
Identifiants
pubmed: 35909163
doi: 10.1186/s13054-022-04107-9
pii: 10.1186/s13054-022-04107-9
pmc: PMC9339193
doi:
Substances chimiques
Vasoconstrictor Agents
0
Norepinephrine
X4W3ENH1CV
Epinephrine
YKH834O4BH
Banques de données
ClinicalTrials.gov
['NCT02908308']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
231Informations de copyright
© 2022. The Author(s).
Références
Intensive Care Med. 2014 Sep;40(9):1210-9
pubmed: 25001475
J Intensive Care Med. 2020 Mar;35(3):219-224
pubmed: 30526209
N Engl J Med. 2013 Dec 5;369(23):2197-206
pubmed: 24237006
Crit Care Med. 2021 Aug 1;49(8):e741-e750
pubmed: 33826582
Ann Intensive Care. 2019 Nov 19;9(1):127
pubmed: 31745738
Intensive Care Med Exp. 2020 Jan 17;8(1):3
pubmed: 31953652
Resuscitation. 2020 Nov;156:A80-A119
pubmed: 33099419
N Engl J Med. 2019 Dec 12;381(24):2327-2337
pubmed: 31577396
Circ Cardiovasc Interv. 2014 Oct;7(5):663-72
pubmed: 25270900
N Engl J Med. 2021 Jun 17;384(24):2283-2294
pubmed: 34133859
Am Heart J. 2019 Nov;217:23-31
pubmed: 31473324
N Engl J Med. 2002 Feb 21;346(8):549-56
pubmed: 11856793
JAMA Netw Open. 2020 Jul 1;3(7):e208215
pubmed: 32701158
N Engl J Med. 2002 Feb 21;346(8):557-63
pubmed: 11856794
Resuscitation. 2019 Mar;136:93-99
pubmed: 30710595
Trials. 2020 Oct 7;21(1):831
pubmed: 33028425
Intensive Care Med. 2022 Mar;48(3):261-269
pubmed: 35089409